Skip to main content
. 2023 Jan 5;33(11):2156–2168. doi: 10.1038/s41379-020-00661-1

Table 2.

Main pathological data of the study population.

Parameters Total (N = 68) Parameters Total (N = 68)
Airways Other lesions
 Tracheobronchial inflammation, n (%)  Number of other pathological lesions detected, n (%)
 Acute, diffuse 24 (35%)  Absent 27 (40%)
 Acute, focal 8 (12%)  1 31 (45%)
 Chronic, diffuse 28 (41%)  2 8 (12%)
 Chronic, focal 0  ≥3 2 (3%)
 Absent 4 (6%)
 Not available 4 (6%)
Alveolar space Alveolar wall
 Acute inflammation, n (%)  Acute inflammation, n (%)
 Present, diffuse 18 (27%)  Present, diffuse 29 (43%)
 Present, focal 11 (16%)  Present, focal 5 (7%)
 Absent 39 (57%)  Absent 34 (50%)
 Chronic inflammation, n (%)  Chronic inflammation, n (%)
 Present, diffuse 55 (81%)  Present, diffuse 59 (87%)
 Present, focal 8 (12%)  Present, focal 6 (9%)
 Absent 5 (7%)  Absent 3 (4%)
Hyaline membranes, n (%) Pneumocyte type II hyperplasia with interstitial fibroblasts, n (%)
 Present, diffuse 42 (61.8%)  Present, diffuse 17 (25%)
 Present, focal 17 (25%)  Present, focal 7 (10%)
 Absent 9 (13.2%)  Absent 44 (65%)
Pneumocyte type II hyperplasia, n (%)
 Present, diffuse 37 (54.4%) Vessels
 Present, focal 9 (13.2%)  Microthrombi, n (%) 44 (65%)
 Absent 22 (32.4%)  Present, diffuse 13 (19%)
 Present, focal 11 (16%)
 Absent
Organizing Pneumonia, n (%)
 Present, diffuse 11 (16%)  Large thrombi, n (%) 22 (32%)
 Present, focal 12 (18%)  Present, diffuse 7 (10%)
 Absent 45 (66%)  Present, focal 39 (58%)
 Absent